论文部分内容阅读
慢性髓性白血病(CML)是一种起源于造血干细胞的恶性增殖性疾病。目前经酪氨酸激酶抑制剂(TKI)治疗的CML患者生存期接近一般人群,在其治疗过程中依从性和持续性尤为重要,在TKI中进行药物选择时,安全谱是必须考量的因素。二代TKI达沙替尼对导致伊马替尼耐药的100多种BCR-ABL突变有效~([1]),与伊马替尼相比能够达到
Chronic myelogenous leukemia (CML) is a malignant proliferative disease that originates from hematopoietic stem cells. CML patients currently treated with tyrosine kinase inhibitors (TKIs) have a survival time close to that of the general population and are of particular importance in their adherence and sustainability during treatment, and safety spectra are factors that must be considered when selecting drugs in TKIs. Second-generation Dasatinib is effective in over 100 mutations of BCR-ABL that cause imatinib resistance [(1)), comparable to imatinib